Premium
Immediate‐Release Oxybutynin versus Tolterodine in Detrusor Overactivity: A Population Analysis
Author(s) -
Lawrence Margareta,
Guay David R. P.,
Benson Steven R.,
Anderson Michael J.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.5.470.35064
Subject(s) - tolterodine , oxybutynin , discontinuation , medicine , population , urology , anesthesia , overactive bladder , alternative medicine , environmental health , pathology
We evaluated adherence to treatment with immediate‐release (IR) oxybutynin (515 patients) and tolterodine (505 patients) for detrusor overactivity through retrospective analysis of a pharmacy claims database. Outcomes included percentage of patients continuing therapy for 6 months, medication possession ratios, and time to discontinuation of therapy. The proportion of patients continuing therapy for 6 months was statistically superior for tolterodine (32%) compared with IR oxybutynin (22%, p<0.001). Medication possession ratios were also superior for patients in the tolterodine group (medians 0.83 and 0.64, ranges 0.11–1.15 and 0.07–1.13, respectively, p<0.001). Oxybutynin was discontinued significantly earlier (mean 45 days) than tolterodine (mean 59 days, p<0.001) and was switched to another therapy more commonly than tolterodine (19% and 14%, respectively). Tolterodine was favored over oxybutynin for several measurements of patient adherence. However, less than one‐third of patients continued therapy with either agent for 6 months. The clinical relevance of these differences is unknown.